Children's Hospital Colorado | Pediatric Infectious Disease

Research site

(Unclaimed)

Location

13123 East 16th Avenue, B-055, Aurora, Colorado, United States of America

Site insights

Top conditions

Top treatments

Ubrogepant

Ozanimod

Mavacamten

Trofinetide

Ribavirin

Ruxolitinib

Repotrectinib

Ombitasvir

ABT-414

Dalbavancin

Parent organization

This site is a part of Children's Hospital Colorado

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 43 total trials

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lympho...

Active, not recruiting

Leukemia

Drug: Methotrexate

Drug: Thioguanine

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or me...

Enrolling

Locally Advanced Solid Tumors

Primary CNS Tumors

Drug: Oral repotrectinib (TPX-0005)

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive...

Enrolling

Cardiomyopathy, Hypertrophic

Drug: Placebo

Drug: Mavacamten

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, rec...

Active, not recruiting

Desmoplastic Small Round Cell Tumor

Drug: Ramucirumab

Drug: Cyclophosphamide

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only

Migraine

Drug: Ubrogepant

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Active, not recruiting

Functional Constipation

Irritable Bowel Syndrome With Constipation

Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)

Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)

Status recently updated

NS-050/NCNP-03 in Boys With DMD (Meteor50)

This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selec...

Not yet enrolling

Enrolling

Duchenne Muscular Dystrophy

Drug: NS-050/NCNP-03

Drug: Placebo

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (Ubro Peds)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling

Migraine

Drug: Placebo-Matching Ubrogepant

Drug: Ubrogepant

Locations recently updated

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. (U-ASTOUND)

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Enrolling

Ulcerative Colitis

Drug: Upadacitinib

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) (NuPower)

SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous...

Active, not recruiting

Mitochondrial Myopathies

Mitochondrial DNA Mutation

Drug: Elamipretide

Drug: Placebo

Werewolf Flow 50 During ACL Reconstruction

The aim of this study is to compare the outcomes, ease of use, and cost of the Werewolf FLOW50 device to the institutional standard of care which is...

Enrolling

Anterior Cruciate Ligament Injuries

Arthrofibrosis of Knee

Device: Werewolf FLOW 50

Other: Control